Navigation Links
Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months

Net Results Improve for Year on Higher Services Revenues, Lower Expenses

POWAY, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Digirad Corporation (Nasdaq: DRAD), a leading provider of medical diagnostic imaging systems and services to physicians' offices, hospitals and imaging centers, today reported narrower losses for the twelve months ended December 31, 2007, on higher annual revenues and lower operating expenses for the year.

Consolidated revenues for the quarter were $18.8 million, up nine percent from $17.2 million in fourth-quarter 2006. Revenue from its mobile imaging services division or DIS rose 16 percent to $13.4 million from $11.6 million in fourth-quarter 2006. Product-related revenue was $5.4 million, and included sales of 18 cameras, compared to $5.6 million in fourth-quarter 2006, including sales of 17 cameras.

Consolidated revenues for full-year 2007 were $73.9 million, compared to $71.9 million in 2006. DIS revenue was $52.4 million, compared to $49.6 million for 2006. Product-related revenue was $21.5 million, including sales of 73 cameras, compared to $22.3 million in 2006, which included sales of 71 cameras.

Chief Executive Officer Mark Casner commented: "We are pleased with our achievements in 2007: our acquisition of Ultrascan, the launch of our Centers of Influence strategy, the improvement in our product margins, and the reduction of our operating loss by $5.4 million compared to 2006."

Consolidated gross profit decreased by nine percent to $4.5 million for the quarter, principally due to decreased DIS profitability attributable to greater than normal seasonality and the disruption in radioisotope supplies announced previously. Gross margin was 24 percent of revenues in the fourth quarter of 2007, compared to 28 percent of revenues in 2006.

Consolidated gross profit for full-year 2007 increased by eight percent to $20.5 million, or 28 percent of revenues, compared to $19.1 million, or 26 percent of revenues in 2006.

Net loss for the quarter was $1.1 million, or $(0.06) per share, compared to a fourth-quarter 2006 net loss of $149,000, or $(0.01) per share. The $1.0 million increase in net loss for fourth-quarter 2007 was due in part to a decline in DIS gross profit, increased amortization costs associated with the intangible assets arising from the Ultrascan acquisition of $185,000, and a fourth-quarter charge of $300,000 primarily from impairment of certain long-term assets.

Despite higher net losses for the fourth quarter, net loss for the year declined more than 75 percent to $1.4 million, or $(0.07) per share, compared to a net loss of $6.3 million, or $(0.34) per share, incurred in 2006. Total operating expenses for full-year 2007 declined to $23.4 million, or 32 percent of revenues, from $27.3 million, or 38 percent of revenues, in 2006.

For the quarter, DIS operated 136 units, both nuclear and ultrasound, with an overall asset utilization rate of 60 percent, compared to 83 units (all nuclear) and an asset utilization rate of 56 percent for fourth-quarter 2006. During the quarter the Company continued to upgrade its mobile imaging services' nuclear camera fleet by replacing six single-head cameras with its multi-headed Cardius XPO configuration. The Company's fleet of mobile cameras now includes 61 multi-headed cameras. The ongoing upgrades are expected to increase reliability and patient throughput and thereby lead to higher utilization and lower labor costs in subsequent periods.

Cash and equivalents and securities available for sale on December 31, 2007, totaled $31.7 million, compared to $44.3 million on December 31, 2006. Cash usage for 2007 included $8.8 million in payments toward the acquisition of Ultrascan net assets and $8.6 million for capital expenditures primarily associated with the fleet upgrade of the Company's mobile imaging services operations. Cash usage was offset in part by positive cash flows from operations of $4.7 million during the year. Net receivables were $8.5 million, compared to $7.5 million on December 31, 2006. Net inventories were $5.5 million, compared to $5.9 million on December 31, 2006.

Focus for 2008

Casner further commented: "Looking forward, our key focus for 2008 will be driving DIS revenue growth through our Centers of Influence strategy, increasing our mobile imaging fleet utilization which should translate into a profitable 2008 for our DIS business, and reaching profitability for the first time in the history of our product business, as we intend to increase product-related revenue, reduce costs and improve reliability in this business segment."

Management Reaffirms Guidance for 2008

For full-year 2008, the Company anticipates consolidated revenues in a range of $80 million to $84 million, consisting of DIS imaging services revenue of $59 million to $61 million and product-related revenue of $21 million to $23 million; and consolidated net results for 2008 to range from net income of $500,000 to a net loss of $1 million, including estimated stock-based compensation expense of $1 million.

Conference Call Information

Digirad has scheduled a conference call at 11:00 a.m. EDT today. A simultaneous webcast of the call may be accessed online from the Events & Presentations link on the Investor Relations page at; an archived replay of the webcast will be available within 15 minutes of the end of the conference call. A telephone replay of the call will be available at (800) 406-7325 or (303) 590-3030, conference ID #3838461, from approximately 2 p.m. EST. The telephone replay will be available until 11:59 p.m. EST on February 9.

About Digirad

Digirad Corporation provides diagnostic nuclear and ultrasound imaging systems and services to physicians' offices, hospitals and other medical services providers for cardiac, vascular, and general imaging applications. Digirad's Cardius XPO line of nuclear imaging cameras use patented solid-state technology and unique multi (single, dual, triple) head design for superior performance and advanced features for sharper digital images, faster processing, compact size, lighter weight for portability, ability to handle patients up to 500 pounds, and improved patient comfort compared to standard nuclear cameras. Digirad's 2020tc general-purpose nuclear imager has a small footprint and may also be configured for fixed or mobile use to supplement primary imaging. Digirad's installed base of nuclear equipment exceeds 500 systems; in addition, a mobile fleet of more than 136 nuclear and ultrasound imaging systems is being used in 23 states, primarily in the eastern, midwestern and southwestern United States. For more information, please visit Digirad(R), Digirad Imaging Solutions(R), and Cardius(R) are registered trademarks of Digirad Corporation.

Forward-Looking Statements

Statements in this press release that are not a description of historical facts are forward looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts and use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" and other words and terms of similar meaning. Examples of such forward looking statements include statements regarding revenue growth, gross margin improvements, declining operating expenses, performance and costs benefits from the ongoing upgrade of the mobile imaging fleet, anticipated revenue in 2008 from the Company's centers of influence strategy, potential acquisitions, and, in general, anticipated financial results for 2008. Actual performance and benefits results may differ materially from those set forth in this press release due to risks and uncertainties inherent in Digirad's business including, without limitation, changes in business conditions, technology, customers' business conditions, work force, suppliers, business prospects, economic outlook, operational policy or structure, acceptance and use of Digirad's camera systems and services, reliability, recalls, and other risks detailed in Digirad's filings with the U.S. Securities and Exchange Commission, including Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward looking statements, which speak only as of the date hereof. All forward looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward looking statements contained herein.

Digirad Corporation

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

(unaudited) (unaudited)


DIS $13,420 $11,606 $52,440 $49,614

Product 5,403 5,641 21,507 22,312

Total revenues 18,823 17,247 73,947 71,926

Cost of revenues:

DIS 10,749 8,595 39,520 37,675

Product 3,582 3,742 13,909 15,192

Total cost of revenues 14,331 12,337 53,429 52,867

Gross profit 4,492 4,910 20,518 19,059

Operating expenses:

Research and development 631 645 3,072 3,894

Sales and marketing 2,009 2,030 7,670 8,827

General and administrative 2,794 2,846 11,920 14,535

Amortization and impairment

of intangible assets 371 (8) 697 27

Total operating expenses 5,805 5,513 23,359 27,283

Loss from operations (1,313) (603) (2,841) (8,224)

Interest income, net 343 454 1,566 1,988

Other expense (130) -- (101) (54)

Net loss $(1,100) $(149) $(1,376) $(6,290)

Net loss per share - basic $(0.06) $(0.01) $(0.07) $(0.34)

and diluted

Weighted average shares


Basic and diluted 18,916 18,791 18,845 18,761

Stock-based compensation expense is included in the above as follows:

Cost of DIS revenue $10 $17 $71 $141

Cost of Product revenue (11) 9 49 74

Research and development 15 -- 77 130

Sales and marketing 35 41 102 279

General and administrative 32 110 606 942

Digirad Corporation

Condensed Consolidated Balance Sheets(1)

(in thousands)

December 31,

2007 2006



Cash and cash equivalents $14,922 $10,070

Securities available-for-sale 16,740 34,256

Accounts receivable, net 8,536 7,534

Inventories, net 5,455 5,860

Other current assets 1,786 1,499

Total current assets 47,439 59,219

Property and equipment, net 16,235 9,570

Other intangible assets, net 2,631 428

Goodwill 2,650 --

Restricted cash 60 60

Total assets $69,015 $69,277

Liabilities and stockholders' equity

Accounts payable $2,650 $2,643

Accrued compensation 3,547 3,650

Accrued warranty 930 788

Other accrued liabilities 3,285 3,306

Deferred revenue 2,909 2,775

Current portion of long-term debt 213 269

Total current liabilities 13,534 13,431

Long-term debt, net of current portion -- 99

Deferred rent 234 302

Total stockholders' equity 55,247 55,445

Total liabilities and stockholders' equity $69,015 $69,277

(1) The condensed consolidated balance sheet as of December 31, 2006, was

derived from the audited financial statements as of that date.

SOURCE Digirad Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy
2. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
3. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
4. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
5. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2007 Earnings Conference Call
7. Baxa Corporation Launches New Web Site
8. CuraGen Corporation Receives Notification from NASDAQ
9. Healionics Corporation Completes Series A Financing
10. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008
11. China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
Post Your Comments:
(Date:10/12/2015)... Oct. 12, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... engaged in developing and commercializing novel treatments in oncology, ... Dennis Turpin , the Company,s former Senior Vice ... its Quebec City office.  ... Chief Executive Officer of the Company commented, "After a ...
(Date:10/12/2015)... October 12, 2015 LabStyle Innovations ... Management Solution, today announced its Medical Director, Dr. ... at MobiHealth,s 5th EAI International Conference on Wireless ... through innovations in mobile and wireless technologies," the conference ... from October 14 - 16, 2015. The conference ...
(Date:10/12/2015)... , Oct. 12, 2015 VolitionRx Limited ... a completed clinical study of its NuQ ® blood-based ... the online issue of Clinical Epigenetics , the official ... conducted in collaboration with Lund University, ... Andersson , MD, PhD, Professor of Surgery and Vice-Dean, Faculty ...
(Date:10/12/2015)... Seattle WA (PRWEB) , ... October 12, 2015 , ... ... for the treatment of retinal diseases that can safely and chronically be administered as ... Global Health Impact Forum co-hosted by The Cleveland Clinic and taking place October 25th ...
Breaking Biology Technology:
(Date:10/6/2015)... , Oct. 6, 2015 Track Group, ... today that it has signed a contract with the ... across the full range of sentences under the Department,s ... of the Americas. "This contract with the Virginia DOC ... the US and advances our position as a trusted ...
(Date:10/5/2015)... ) releases ... (NASDAQ: NXTD ), a biometric authentication company focused ... ) releases the following market and ... a biometric authentication company focused on the growing mobile ... ) releases the following market and ...
(Date:10/1/2015)... Oct. 1, 2015  Biometrics includes diverse set ... body characteristics, such as fingerprints, eye retinas, facial ... of biometrics technology has been constantly increasing in ... five years. In addition to the most prominent ... recognition, other means of biometric authentication are rapidly ...
Breaking Biology News(10 mins):